BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

BTIG raised the firm’s price target on Guardant Health (GH) to $60 from $55 and keeps a Buy rating on the shares after its Q4 earnings beat and ...

Wall Street is gearing up for another wave of blank check companies from seasoned and first-time sponsors, showing the ...

Medical Technology Analyst Zimmerman holds a virtual meeting with EVP & CFO Saccaro and Chief Investor Relations Officer Borders on February 21 ...

Investing.com -- BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025. The brokerage ...

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG Life Sciences and Diagnostic Tools Analyst Massaro holds group dinner meeting with CEO Stueland and CFO Feeley on January 13 at 10:30 am. Discover outperforming stocks and invest smarter with ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

BTIG lowered the firm’s price target on Evolent Health (EVH) to $20 from $29 but keeps a Buy rating on the shares. The firm notes it was disappointed by the company’s comments around higher ...